Akero Therapeutics Inc's Comment on Sales, Marketing and Customers
The text addresses laws and regulations relevant to the marketing and distribution of products, including anti-kickback statutes, fraud and abuse laws, false claims acts, and transparency requirements. It also covers data privacy and security regulations such as HIPAA, HITECH, CCPA, and WA MHMDA. These regulations apply to healthcare providers, health plans, healthcare clearinghouses, and covered entities managing personal and health information.
Recent presentations by Akero Therapeutics and HistoIndex at the 2025 EASL Congress have brought forward significant advancements in the understanding and assessment of liver fibrosis, specifically in the context of the Phase 2b HARMONY trial. Utilizing AI-based digital pathology to evaluate histopathological responses, these analyses underscore the promise that novel therapies like efruxifermin (EFX) hold for patients with compensated cirrhosis secondary to metabolic dysfunction-associated steatotic liver disease (MASH). This article aims to review the pivotal findings of the trial and examine the emerging role of AI in histopathological assessments, enhancing conventional methods and potentially advancin...
Akero Therapeutics Presents Promising Results from Phase 2b HARMONY Study at AASLD The Liver Meeting 2024 Akero Therapeutics has recently announced its decision to present new insights from its Phase 2b HARMONY study at the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024. This annual meeting is one of the most significant platforms for liver disease research, drawing healthcare professionals, researchers, and industry leaders from around the world to share breakthroughs in hepatology.The HARMONY study has been pivotal in evaluating the safety and efficacy of Efruxifermin (EFX), a novel therapeutic agent targeting nonalcoholic steatohepatitis (NASH), a progressi...
In a significant development for the field of nonalcoholic steatohepatitis (NASH) treatment, Akero Therapeutics has recently announced the dosing of the first patients in their Phase 3 SYNCHRONY Program for efruxifermin. This milestone builds upon the successful Phase 2b HARMONY results and holds promise for millions of patients suffering from pre-cirrhotic NASH or nonalcoholic steatohepatitis with fibrosis (F2-F3). With the potential to radically transform the management of this chronic liver disease, Akero Therapeutics efruxifermin is an eagerly awaited therapeutic intervention. Phase 3 SYNCHRONY Program: The Journey to a Potential Breakthrough Treatment The initiation of the Phase 3 SYN...
Akero Therapeutics Inc’s Comment on Sales, Marketing and Customers
The text addresses laws and regulations relevant to the marketing and distribution of products, including anti-kickback statutes, fraud and abuse laws, false claims acts, and transparency requirements. It also covers data privacy and security regulations such as HIPAA, HITECH, CCPA, and WA MHMDA. These regulations apply to healthcare providers, health plans, healthcare clearinghouses, and covered entities managing personal and health information.
Sources:
Akero Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Akero Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Akero Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
